Medicare Part D Redesign (2025)

How It Works

The 2025 Part D redesign is the most consequential structural change to Medicare drug coverage since the benefit launched in 2006. Under the new design, beneficiaries face a $590 deductible (2025), 25% coinsurance in the initial coverage phase, and then a hard $2,000 annual out-of-pocket cap. Once the cap is hit, Medicare pays 100% of remaining drug costs for the calendar year. Behind the scenes, liability shifts dramatically: in the initial coverage phase, plans cover 65% (up from 75%) and manufacturers discount 10% on brands; in the catastrophic phase, plans now cover 60%, manufacturers discount 20%, and Medicare pays only 20% (down from 80% in the old design). This shift is designed to give plans stronger incentives to negotiate against high-list-price drugs, since they now bear more catastrophic-phase risk. The redesign also launches the Medicare Prescription Payment Plan (MPPP), an optional election that lets beneficiaries pay their OOP in level monthly installments instead of up front, intended to help patients on expensive January starts (e.g., a patient starting Revlimid in January would previously have paid roughly $3,400 in the first month; MPPP spreads that across the year). CBO projects the redesign will save Medicare beneficiaries roughly $7.4 billion annually in OOP costs. The $2,000 cap is indexed to Part D per-capita cost growth after 2025. LIS (Extra Help) enrollees, previously capped near $0-10 copays, see minimal change.

Related Terms

• Medicare Part D, The prescription drug benefit within Medicare, covering outpatient medications for 50+ million Americans aged 65+ and those with disabilities.
• Out-of-Pocket Cost, The amount a patient pays directly for a prescription drug, including copays, coinsurance, and deductible payments.
• IRA Medicare Drug Negotiation, The process under the Inflation Reduction Act where CMS negotiates a "maximum fair price" directly with manufacturers for selected high-cost Medicare drugs.
• Donut Hole (Coverage Gap), A phase in Medicare Part D where patients historically paid a higher share of drug costs after exceeding initial coverage but before reaching catastrophic coverage.